Adjuvant Therapy for Node-Positive Colon Cancer

Haider A. Shirazi, Mamta Singhvi, William Small, Al B. Benson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The adjuvant therapy for node positive colon cancer (stage III) reflects an evolutionary process incorporating strategies based on risk assessment and expansion of therapeutic options. Risk assessment is currently determined by pathologic features including grade of tumor, T-stage and nodal status, as well as number of lymph nodes reported. There is a growing interest in the utilization of molecular markers as a risk stratification strategy. Such, current randomized colon clinical trials include the collection of tumor specimens for molecular assessment and multivariate analyses of prognostic and predictive factors. Most recent clinical trials have established the efficacy of oxaliplatin, 5-FU and leucovorin as the standard of care for stage III colon cancer patients. In addition, the monoclonal antibodies, bevacizumab and cetuximab, have been integrated into recent randomized clinical trial designs, based on efficacy data from advanced disease trials.

Original languageEnglish (US)
Pages (from-to)191-196
Number of pages6
JournalSeminars in Colon and Rectal Surgery
Volume19
Issue number4
DOIs
StatePublished - Dec 2008

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Fingerprint Dive into the research topics of 'Adjuvant Therapy for Node-Positive Colon Cancer'. Together they form a unique fingerprint.

Cite this